Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fast PCR test could speed up right antibiotic choice for blood infections

NCT ID NCT07408544

Knowledge-focused Sponsor: Istanbul Medipol University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a rapid PCR test that identifies bacteria and drug resistance in about an hour, compared to standard methods that take 1-3 days. 300 adults with bloodstream infections will be randomly assigned to get either the rapid test plus standard care or standard care alone. The goal is to see if the rapid test helps doctors start the most effective, narrow-spectrum antibiotic sooner, which could improve recovery and reduce side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adult hospitalized patients (≥18 years of age) with clinical suspicion of bloodstream infection and a confirmed positive blood culture signal. Eligible participants are recruited from medical and surgical wards as well as intensive care units of a tertiary university hospital. Patients with various underlying comorbid conditions, including immunosuppression and malignancy, are included in order to reflect real-world clinical practice. Only patients with a first episode of bloodstream infection during the study period are eligible for enrollment.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * Clinical suspicion of bloodstream infection * Positive blood culture signal * Patients managed in hospital wards or intensive care units * Ability to provide informed consent (patient or legally authorized representative) Exclusion Criteria: * Recurrent episode of the same bloodstream infection * Inadequate or insufficient blood culture sample for analysis * Refusal or inability to provide informed consent * Death within the first 24 hours after blood culture collection * Loss to follow-up during the study period

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bacteremia and sepsis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bacterial infectious disease with sepsis Fungemia Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bacteremia and sepsis Bloodstream infections Fungemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Istanbul Medipol University Hospital

    RECRUITING

    Istanbul, Bagcılar, 34218, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.